Cabozantinib: A Review in Advanced Renal Cell Carcinoma

被引：23

作者：

Al-Salama, Zaina T. ^{[1
]}

Keating, Gillian M. ^{[1
]}

机构：

[1] Springer, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2016年 / 76卷 / 18期

关键词：

EVEROLIMUS; PHARMACOKINETICS; THERAPIES; MET;

D O I：

10.1007/s40265-016-0661-5

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

The multiple tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx (TM)) is approved in the USA for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the EU, cabozantinib is indicated for the treatment of advanced RCC in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. In adults with advanced or metastatic clear-cell RCC who had previously received VEGF receptor (VEGFR) TKIs, progression-free survival (PFS) and overall survival (OS) were significantly prolonged in patients who received oral cabozantinib versus oral everolimus in the pivotal METEOR trial. Objective response was achieved in a significantly higher proportion of patients receiving cabozantinib than those receiving everolimus. Cabozantinib had a manageable adverse events profile in patients with advanced RCC. Thus, cabozantinib is an important new option for use in patients with advanced RCC who have previously received antiangiogenic therapy.

引用

页码：1771 / 1778

页数：8

共 22 条

[1]

[Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship

[2]

IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). [J].

Atkins, Michael B. ;

McDermott, David F. ;

Powles, Thomas ;

Motzer, Robert J. ;

Rini, Brian I. ;

Fong, Lawrence ;

Joseph, Richard Wayne ;

Pal, Sumanta K. ;

Sznol, Mario ;

Hainsworth, John D. ;

Stadler, Walter Michael ;

Hutson, Thomas E. ;

Ravaud, Alain ;

Bracarda, Sergio ;

Suarez, Cristina ;

Choueiri, Toni K. ;

Qiu, Jiaheng ;

Huseni, Mahrukh A. ;

Schiff, Christina ;

Escudier, Bernard J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[3]

Cella D, 2016, ANN ONCOL S, V27, pvi282

[4]

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Escudier, B. ;

Powles, T. ;

Mainwaring, P. N. ;

Rini, B. I. ;

Donskov, F. ;

Hammers, H. ;

Hutson, T. E. ;

Lee, J-L ;

Peltola, K. ;

Roth, B. J. ;

Bjarnason, G. A. ;

Geczi, L. ;

Keam, B. ;

Maroto, P. ;

Heng, D. Y. C. ;

Schmidinger, M. ;

Kantoff, P. W. ;

Borgman-Hagey, A. ;

Hessel, C. ;

Scheffold, C. ;

Schwab, G. M. ;

Tannir, N. M. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) :1814-1823

[5]

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

[6]

Epidemiology and risk factors for kidney cancer [J].

Chow, Wong-Ho ;

Dong, Linda M. ;

Devesa, Susan S. .

NATURE REVIEWS UROLOGY, 2010, 7 (05) :245-257

[7]

Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies [J].

Eisen, Tim ;

Sternberg, Cora N. ;

Robert, Caroline ;

Mulders, Peter ;

Pyle, Lynda ;

Zbinden, Stephan ;

Izzedine, Hassan ;

Escudier, Bernard .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2012, 104 (02) :93-113

[8]

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Escudier, B. ;

Porta, C. ;

Schmidinger, M. ;

Algaba, F. ;

Patard, J. J. ;

Khoo, V. ;

Eisen, T. ;

Horwich, A. .

ANNALS OF ONCOLOGY, 2014, 25 :49-56

[9]

Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study [J].

Escudier, Bernard J. ;

Powles, Thomas ;

Motzer, Robert J. ;

Olencki, Thomas ;

Aren, Osvaldo Rudy ;

Oudard, Stephane ;

Bracarda, Sergio ;

Tomczak, Piotr ;

Castellano, Daniel E. ;

Appleman, Leonard Joseph ;

Drabkin, Harry A. ;

Vaena, Daniel A. ;

Milwee, Steven ;

Youkstetter, Jillian ;

Choueiri, Toni K. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[10]

European Medicines Agency, 2016, CABOM CAB FILM COAT

← 1 2 3 →